Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Asian Stocks Waver as Trump Signals Fed Pick, Shutdown Deal and Tech Earnings Stir Markets 
Copper Prices Hit Record Highs as Metals Rally Gains Momentum on Geopolitical Tensions 
Oil Prices Surge Toward Biggest Monthly Gains in Years Amid Middle East Tensions 
Wall Street Slips as Tech Stocks Slide on AI Spending Fears and Earnings Concerns 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
U.S. and El Salvador Sign Landmark Critical Minerals Agreement to Boost Investment and Trade 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster 
Philippine Economy Slows in Late 2025, Raising Expectations of Further Rate Cuts 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Google Halts UK YouTube TV Measurement Service After Legal Action 
Gold Prices Pull Back After Record Highs as January Rally Remains Strong 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
The Maire - EuroChem Case: Three Lessons for Global Business 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Bristol Myers and AbbVie are reportedly planning to terminate some of their staff in California. The job cuts will be the latest in a string of layoffs in the biopharma industry in the United States.
As per Reuters, a combined total of 360 job roles are set to be affected by the plan. Both Bristol Myers Squibb Co, and AbbVie Inc. reportedly informed the officials of the California administration that they will eliminate some of their employees.
The notices were said to have been filed last week with the state but were only made public a few days after. In the filing, Bristol Myers Squibb indicated that it will remove up to 261 jobs in its offices in two locations in San Diego, California. As of AbbVie, it told the state it will be slashing some 99 jobs in Irvine.
The company’s spokesman said that the layoffs at Bristol Myers are taking place after the company acquired Turning Point Therapeutics Inc. for $4.1 billion. The biopharma’s acquisition deal with the San Diego-based biotech drug developer closed just last month.
Fierce Pharma reported that the job cut notices were separately filed by Bristol Myers and AbbVie under the Worker Adjustment and Retraining Notification (WARN) alerts. The filing is to officially inform California that there will be layoffs from their companies this November.
With the move, Bristol Myers and AbbVie have joined other major biopharmaceutical firms such as Novartis and Biogen in the reduction of their workforce. At any rate, BMS’s job cuts are related to its latest acquisition deal of Turning Point Therapeutics and this was confirmed by the company through its spokesman.
“We are very pleased to have completed the acquisition of Turning Point Therapeutics to further strengthen our leading oncology franchise,” the company said in a separate statement. “As part of the integration, all incoming employees received retention packages tied to continued service to BMS for a period of time and have been encouraged to apply to long-term roles at BMS after their retention period ends.”
Meanwhile, AbbVie was not able to respond immediately to a request for comment regarding the job cuts.
